 |
|||||||||||||||||||||||
|
|||||||||||||||||||||||
 |
|||||||||||||||||||||||
Dear Participant:
On behalf of the National Cancer Institute's Clinical Proteomic Technologies for Cancer initiative (CPTC), I welcome you to the CPTC Fourth Annual Meeting, September 8-9, 2010, at the Bethesda North Marriott Hotel and Conference Center in Maryland.
CPTC is a nationwide, interdisciplinary group of partnerships among institutions and individuals working to establish and advance a more reliable and efficient biomarker development pipeline. CPTC's investigators are achieving this goal by addressing and reducing the layers of variability at every step of the biomarker development pipeline, from experimental design through data analysis.
As a result, CPTC is the leader in defining proteomic platform performance parameters and standards to characterize proteomic states associated with cancer. These advances are anticipated to produce credentialed candidate leads for potential biomarkers and increase the current understanding of cancer biology. It is anticipated that CPTC's work will have far-reaching impacts, including the ultimate goal of reducing the burden of suffering and death due to cancer.
CPTC has achieved tremendous progress which is indicative of both the dedication to the highest quality of research by its investigators and open standards. It has demonstrated the effectiveness of a multi-disciplinary, multi-institutional approach – and in doing so, addressed long-standing problems of variability issues in proteomics that result from analytical platforms versus measuring real biological differences. This year's event will focus on key areas where CPTC has made significant achievements, including Development and Implementation of a New Cancer Proteome Biomarker Pipeline; Regulatory Science; Open Data Access Policies; and Renewable Affinity Reagents.
The Annual Meeting will also feature speakers and participants from genomic organizations, as linking genomic knowledge to proteomics will aid in the identification of high-value protein targets that can drive the rational development of new diagnostics and therapies to achieve personalized cancer medicine.
I look forward to seeing you in Bethesda!
Sincerely,
Henry Rodriguez, Ph.D., M.B.A.
Director, Office of Cancer Clinical Proteomics Research
|
|
     |